A Parallel Study Evaluating the Safety of Lactospore® in Healthy Individuals

NCT ID: NCT02176889

Last Updated: 2014-09-09

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1

Total Enrollment

40 participants

Study Classification

INTERVENTIONAL

Study Start Date

2014-06-30

Study Completion Date

2014-08-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to determine whether Lactospore is safe in healthy adults.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Healthy

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Blinding Strategy

DOUBLE

Participants Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Lactospore

One tablet once daily, 30 minutes before a meal, preferably in the morning for 30 days

Group Type EXPERIMENTAL

Lactospore

Intervention Type DIETARY_SUPPLEMENT

Bacillus coagulans MTCC 5856

Placebo

One tablet once daily, 30 minutes before a meal, preferably in the morning, for 30 days.

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type OTHER

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Lactospore

Bacillus coagulans MTCC 5856

Intervention Type DIETARY_SUPPLEMENT

Placebo

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Male or female ≥18 years of age
* If female, subject is not of child bearing potential or female subject of childbearing potential must agree to use a medically approved method of birth control and have a negative urine pregnancy test result.
* Healthy as determined by laboratory results and medical history
* Normal BMI 18.5 - 29.9 kg/m2
* Has given voluntary, written, informed consent to participate in the study

Exclusion Criteria

* Women who are pregnant, breastfeeding, or planning to become pregnant during the course of the trial
* Subject has any clinically significant medical conditions
* Subject requires the use of prescribed medications (other than birth control)
* Use of illicit drugs or history of drug or alcohol abuse with the past 5 years (currently having more than 2 standard alcoholic drinks per day)
* Participation in a clinical research trial within 30 days prior to randomization
* Clinically significant abnormal laboratory results at screening
* Allergy or sensitivity to test product ingredients
* Individuals who are cognitively impaired and/or who are unable to give informed consent
* Any other condition which in the Investigator's opinion may adversely affect the subject's ability to complete the study or its measures or which may pose significant risk to the subject
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Sabinsa Corporation

INDUSTRY

Sponsor Role collaborator

KGK Science Inc.

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Dale Wilson, MD

Role: PRINCIPAL_INVESTIGATOR

KGK Science Inc.

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

KGK Synergize Inc.

London, Ontario, Canada

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Canada

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

14PSHS

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Tolerance of a Probiotic Formula
NCT03925558 COMPLETED NA
Synbiotics and Growth
NCT01886898 COMPLETED PHASE3